

DIVERSIFIED GLOBAL SPECIALTY PHARMACEUTICAL COMPANY WELL-POSITIONED FOR LONG-TERM SUCCESS

BUILDING ON OUR 155-YEAR HISTORY OF PROVIDING MEDICINES THAT ADDRESS PATIENT NEEDS

Creating value for our patients, customers, partners, team members, shareholders and other stakeholders



Our Future Is Here

Serving patients through two business segments:

- **Specialty Brands:** global, innovative biopharmaceutical business developing and commercializing specialty branded pharmaceutical medicines
- **Specialty Generics:** U.S.-based, vertically integrated business producing high-quality generic medicines and active pharmaceutical ingredients in complex markets

Supported by **existing drug development programs** and **-2,800 talented employees globally**



Welcoming New Leadership and a New Board

Sigurdur “Siggi” Olafsson appointed President and Chief Executive Officer, effective June 25, 2022, bringing almost **30 years of experience across branded and generic drugs**

Six new, independent directors appointed to Board, along with Siggi

Incoming CEO and Board bring decades of **experience, relevant expertise and new perspectives** to help drive the Company’s next phase



Focused on Delivering Sustainable Value for All Stakeholders

New Board and management committed to **thoughtfully reviewing business and developing go-forward strategy**

Building on **innovation-driven therapies pipeline**, capitalizing on **core strengths** and positioning the Company for **long-term sustainable growth**

SUCCESSFULLY COMPLETED CHAPTER 11 REORGANIZATION PROCESS



Reduced debt by ~\$1.3B, strengthened balance sheet and increased financial flexibility



Permanently resolved key litigation claims related to opioids and Acthar® Gel, among others



Positioned to invest in the business, execute on strategic initiatives & advance pipeline

